No headlines found.
Globe Newswire (Thu, 29-Oct 8:30 AM ET)
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
Globe Newswire (Wed, 14-Oct 8:30 AM ET)
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
Globe Newswire (Tue, 13-Oct 8:30 AM ET)
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
Globe Newswire (Thu, 1-Oct 8:30 AM ET)
Globe Newswire (Tue, 22-Sep 8:30 AM ET)
SAB BIO to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 1-Sep 8:30 AM ET)
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
Globe Newswire (Thu, 6-Aug 7:30 AM ET)
Sab Biotherapeutics - Warrant trades on the stock market under the symbol SABSW.
As of November 4, 2026, SABSW stock price was flat at $0.00 with million shares trading.
SABSW has a beta of 0.61, meaning it tends to be less sensitive to market movements. SABSW has a correlation of 0.00 to the broad based SPY ETF.
SABSW has a market cap of $0.00. This is considered a Sub-Micro Cap stock.
In the last 3 years, SABSW traded as high as $.20 and as low as $.00.
SABSW has underperformed the market in the last year with a price return of -96.8% while the SPY ETF gained +13.5%. SABSW has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -93.5% and -82.0%, respectively, while the SPY returned +1.6% and -0.1%, respectively.
SABSW support price is $.00 and resistance is $.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SABSW shares will trade within this expected range on the day.
